Predictors of pneumococcal vaccination uptake in hospitalized patients aged 65 years and over shortly following the commencement of a publicly funded national pneumococcal vaccination program in Australia

被引:18
作者
Ridda, Iman
MacIntyre, Raina C.
Lindley, Richard I.
McIntyre, Peter B.
Sullivan, John
Gilbert, Gwendolyn
Kovoor, Prarnesh
Manolios, Nicholas
Fox, John
机构
[1] Natl Ctr Immunisat Res & Surveillance, Sydney, NSW, Australia
[2] Univ Sydney, Discipline Pediat & Child Hlth, Sydney, NSW 2006, Australia
[3] Univ Sydney, Discipline Med, Dept Cardiol, Sydney, NSW 2006, Australia
[4] Univ Sydney, Discipline Med, Dept Rheumatol, Sydney, NSW 2006, Australia
[5] Univ Sydney, Transfus Med & Immunogenet Res Unit, Sydney, NSW 2006, Australia
[6] Univ Sydney, Cent Clin Sch, Sydney, NSW 2006, Australia
[7] Australian Red Cross Blood Serv, Sydney, NSW, Australia
[8] Westmead Hosp, Inst Clin Pathol & Med Res, Ctr Infect Dis & Microbiol, Sydney, NSW 2145, Australia
[9] Westmead Hosp, Dept Orthopaed Surg, Discipline Med, Sydney, NSW 2145, Australia
来源
HUMAN VACCINES | 2007年 / 3卷 / 03期
关键词
pneumococcal vaccine; hospitalized elderly; increased vaccination uptake;
D O I
10.4161/hv.3.3.3925
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
In January 2005, Australia became the first country to introduce a publicly funded pneumococcal vaccination program for persons 65 years and older which is free at point of service, although the vaccine cost had previously been partially subsidized. Hospitalization in this age group is an important indicator of risk of invasive pneumococcal disease but vaccine uptake has been suboptimal. To determine vaccination rates and predictors of vaccination in the elderly hospitalised patients before and after January 2005. We validated vaccination status against general practitioner (GP) records for patients aged >= 65 years admitted to a large teaching hospital in Sydney between 16th of May 2005 and the 20,h of February 2006 and examined predictors of vaccination. Commencement of the new program resulted in a significant increase in vaccination uptake from 39% of inpatients prior to the free program to 73% in the some cohort of inpatients post January 2005. We found that patient recall of vaccination status was not reliable. Self-report of pneumococcal vaccination had a sensitivity of 0.53 and a specificity of 0.55, highlighting that validation of vaccination status is required. Age over 80 years and dementia significantly predicted under-vaccination. This highlights the importance of integrating free vaccine supply and delivery in primary care to achieve high vaccination coverage. However, demented patients and the very elderly remain under-vaccinated, despite being admitted to hospital for active management of acute conditions.
引用
收藏
页码:83 / 86
页数:4
相关论文
共 36 条
[1]   Assessment of vaccine coverage following the introduction of a publicly funded pneumococcal vaccine program for the elderly in Victoria, Australia [J].
Andrews, RM .
VACCINE, 2005, 23 (21) :2756-2761
[2]   Effectiveness of a publicly funded pneumococcal vaccination program against invasive pneumococcal disease among the elderly in Victoria, Australia [J].
Andrews, RM ;
Counahan, ML ;
Hogg, GG ;
McIntyre, PB .
VACCINE, 2004, 23 (02) :132-138
[3]  
[Anonymous], 1997, MMWR Recomm Rep, V46, P1
[4]  
[Anonymous], 2003, MMWR MORBIDITY MORTA
[5]   Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults [J].
Briss, PA ;
Rodewald, LE ;
Hinman, AR ;
Shefer, AM ;
Strikas, RA ;
Bernier, RR ;
Carande-Kulis, VG ;
Yusuf, HR ;
Ndiaye, SM ;
Williams, SM .
AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2000, 18 (01) :97-140
[6]   Pneumococcal Vaccines: History, Current Status, and Future Directions [J].
Butler, Jay C. ;
Shapiro, Eugene D. ;
Carlone, George M. .
AMERICAN JOURNAL OF MEDICINE, 1999, 107 (01) :69-76
[7]  
*COMM DEP HLTH AG, 2003, AUSTR IMM HDB
[8]  
Condon L., 2002, Health Education Journal, V61, P180, DOI 10.1177/001789690206100208
[9]   Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults:: a meta-analysis of randomized trials [J].
Cornu, C ;
Yzèbe, D ;
Léophonte, P ;
Gaillat, J ;
Boissel, JP ;
Cucherat, M .
VACCINE, 2001, 19 (32) :4780-4790
[10]   Influenza vaccination as secondary prevention for cardiovascular disease: A science advisory from the American Heart Association/American College of Cardiology (vol 114, pg 1549, 2006) [J].
Davis, M. M. ;
Mensah, G. A. ;
Taubert, K. ;
Baddour, L. M. ;
Benin, A. L. ;
Dunbar, S. .
CIRCULATION, 2006, 114 (22) :E616-E616